Radiology, Vol 188, 53-59, Copyright © 1993 by Radiological Society of North America

ARTICLES

Hepatocellular tumors: characterization with Mn-DPDP-enhanced MR imaging

NM Rofsky, JC Weinreb, ME Bernardino, SW Young, JK Lee and ME Noz
Department of Radiology, New York University Medical Center, Tisch Hospital, NY 10016.

Fifty-eight patients suspected of having focal hepatic disease were studied prior to and following the intravenous administration of manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'- bis(phosphate) (DPDP), a hepatobiliary magnetic resonance (MR) contrast agent. Four doses (3, 5, 8, or 10 mumol/kg) of Mn-DPDP were used to test the hypothesis that Mn-DPDP-enhanced MR imaging would display enhancement in tumors of hepatocellular origin. A total of 203 lesions were evaluated. Histologic proof was available in 32 cases, and in 26 cases lesions were evaluated on the basis of characteristic imaging findings. Statistical calculations for distinction of tumors of hepatocellular origin yielded a sensitivity of 100%, a specificity of 92.0%, an accuracy of 93.6%, a positive predictive value of 75.9%, and a negative predictive value of 100%. The authors conclude that the presence and patterns of enhancement at Mn-DPDP-enhanced MR imaging permit reliable distinction between hepatocellular and nonhepatocellular tumors.

This article has been cited by other articles:

				Y. K. Kim, C. S. Kim, G. H. Chung, Y.-M. Han, S. Y. Lee, S. B. Chon, and J. M. Lee Comparison of Gadobenate Dimeglumine-Enhanced Dynamic MRI and 16-MDCT for the Detection of Hepatocellular Carcinoma Am. J. Roentgenol., January 1, 2006; 186(1): 149 - 157. [Abstract] [Full Text] [PDF]

				Y. K. Kim, H. S. Kwak, C. S. Kim, G. H. Chung, Y. M. Han, and J. M. Lee Hepatocellular Carcinoma in Patients with Chronic Liver Disease: Comparison of SPIO-enhanced MR Imaging and 16-Detector Row CT Radiology, December 21, 2005; (2005) 2381042193. [Abstract] [Full Text]

				J. H. Youk, J. M. Lee, and C. S. Kim MRI for Detection of Hepatocellular Carcinoma: Comparison of Mangafodipir Trisodium and Gadopentetate Dimeglumine Contrast Agents Am. J. Roentgenol., October 1, 2004; 183(4): 1049 - 1054. [Abstract] [Full Text] [PDF]

				P Manoharan and J Ward MRI in the assessment of focal liver lesions in the non-cirrhotic patient Imaging, September 1, 2004; 16(4): 338 - 350. [Abstract] [Full Text] [PDF]

				C. S. Zuo, P. R. Seoane, J. Hu, P. P. Harnish, and N. M. Rofsky MR Imaging of the Stomach: Potential Use for Mangafodipir Trisodium-- A Study in Swine Radiology, July 1, 2004; 232(1): 160 - 163. [Abstract] [Full Text] [PDF]

				S. K. Kim, S. H. Kim, W. J. Lee, H. Kim, J. W. Seo, D. Choi, H. K. Lim, S. J. Lee, and J. H. Lim Preoperative Detection of Hepatocellular Carcinoma: Ferumoxides-Enhanced Versus Mangafodipir Trisodium--Enhanced MR Imaging Am. J. Roentgenol., September 1, 2002; 179(3): 741 - 750. [Abstract] [Full Text] [PDF]

				M. Oudkerk, C. G. Torres, B. Song, M. Konig, J. Grimm, J. Fernandez-Cuadrado, B. Op de Beeck, M. Marquardt, P. van Dijk, and J. C. de Groot Characterization of Liver Lesions with Mangafodipir Trisodium-enhanced MR Imaging: Multicenter Study Comparing MR and Dual-Phase Spiral CT Radiology, May 1, 2002; 223(2): 517 - 524. [Abstract] [Full Text] [PDF]

				G. N. Mann, H. F. Marx, L. L. Lai, and L. D. Wagman Clinical and Cost Effectiveness of a New Hepatocellular MRI Contrast Agent, Mangafodipir Trisodium, in the Preoperative Assessment of Liver Resectability Ann. Surg. Oncol., August 1, 2001; 8(7): 573 - 579. [Abstract] [Full Text] [PDF]

				L. Grazioli, G. Morana, M. P. Federle, G. Brancatelli, M. Testoni, M. A. Kirchin, K. Menni, L. Olivetti, N. Nicoli, and C. Procacci Focal Nodular Hyperplasia: Morphologic and Functional Information from MR Imaging with Gadobenate Dimeglumine Radiology, December 1, 2001; 221(3): 731 - 739. [Abstract] [Full Text] [PDF]